| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Finance & CAO | SVP, Finance | SVP, Finance
1 company
Elvia Cowan is SVP, Finance & CAO at PCVX. Elvia Cowan's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.7M at current prices.
Our model assigns Elvia Cowan a strong insider score of 71/100, based on 8 past trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +45.7%.
The PCVX filings lean toward selling, a net 64,693 shares.
Elvia Cowan has 20 Form 4 filings on record from March 2023 to October 2026, all as SVP, Finance & CAO at Vaxcyte (PCVX), 2023–2026.
The 48 reported transactions were 14 tax withholdings, 13 open-market sales, 9 option exercises and 6 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 9 sales worth about $4.9M.
The largest open-market sale was 19,000 shares of PCVX at an average $86.74 on October 5, 2026, about $1.6M.
8 of the 9 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other was not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | PCVX Vaxcyte, Inc. | SVP, Finance & CAO | Sale+OE10b5-1 | 19,000 | $86.74 | $1,648,060.00 | -40.5% | - | - | |
| Apr 7, 2026 | PCVX Vaxcyte, Inc. | SVP, Finance & CAO | Sale+OE10b5-1 | 3,000 | $60.00 | $180,000.00 | -9.4% | -6.1% | - | |
| Mar 17, 2026 | PCVX Vaxcyte, Inc. | SVP, Finance & CAO | Sell10b5-1 | 1,892 | $55.57 | $105,146.98 | -6.1% | -10.7% | - | |
| Mar 11, 2026 | PCVX Vaxcyte, Inc. | SVP, Finance & CAO | Sale+OE10b5-1 | 2,500 | $58.59 | $146,481.75 | -7.5% | -18.5% | - | |
| Dec 23, 2025 | PCVX Vaxcyte, Inc. | SVP, Finance | Sell | 11,623 | $47.92 | $556,971.85 | -44.4% | +17.0% | - | |
| Sep 3, 2024 | PCVX Vaxcyte, Inc. | SVP, Finance | Sale+OE10b5-1 | 5,000 | $107.67 | $538,350.00 | -28.2% | -16.8% | -70.9% | |
| Jul 16, 2024 | PCVX Vaxcyte, Inc. | SVP, Finance | Sale+OE10b5-1 | 5,000 | $85.00 | $425,000.00 | -28.2% | +35.9% | -56.1% | |
| Jul 8, 2024 | PCVX Vaxcyte, Inc. | SVP, Finance | Sale+OE10b5-1 | 5,000 | $80.00 | $400,000.00 | -28.2% | +36.7% | -57.8% | |
| Mar 1, 2024 | PCVX Vaxcyte, Inc. | SVP, Finance | Sale+OE10b5-1 | 11,678 | $74.08 | $865,070.44 | -48.3% | -2.1% | +1.8% |